GSK’s blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market, the company said on Monday.
Oncology is a key area of focus for GSK as a standalone prescription medicine and vaccine business and its shares fell 3 percent after its statement, which raised concerns that regulatory approval of Blenrep may be rescinded.
Blenrep did not meet the primary endpoint of “progression-free survival”—or the period of time that a person lives with the disease without it getting worse after treatment—in patients with relapsed or refractory multiple myeloma, GSK said….